Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
Ziyi Xu, Xuezhi Hao, Qi Wang...
https://pubmed.ncbi.nlm.nih.gov/36870951/Actively Recruiting
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-07-29
40
Participants Needed
1
Research Sites
26 weeks
Total Duration
Leptomeningeal metastases LM are a rare but serious form of spread in advanced non-small cell lung cancer NSCLC, often linked to EGFR mutations and associated with a poor outlook. Researchers aim to evaluate whether high-dose Firmonertinib combined with intrathecal chemotherapy can improve treatment outcomes for patients with EGFR mutant NSCLC who develop LM. This study also explores the potential of cerebrospinal fluid CSF circulating free DNA cfDNA as a biomarker to monitor treatment response in LM, addressing the current lack of effective monitoring tools. Participants will receive Firmonertinib at 160 mg orally once daily along with intrathecal injections of pemetrexed. The dosage of pemetrexed depends on body weight for those above 50 kg, an induction phase with 40 mg on days 1 and 5 every 3 weeks for 4 cycles followed by consolidation with 40 mg every 4 weeks until CSF ctDNA is negative for those below 50 kg, similar schedules apply with 30 mg doses. This prospective, multicenter, single-arm trial assesses the safety and efficacy of this combined high-dose targeted and local chemotherapy approach. During the study, participants will undergo dynamic monitoring of cfDNA levels in both cerebrospinal fluid and peripheral blood to evaluate treatment effects and safety. The primary outcome is progression-free survival over 2 years. Patients will have regular assessments including laboratory tests and lumbar punctures for CSF collection, and their physical condition will be monitored to ensure adherence and manage side effects. The study spans from April 2025 to November 2027, providing comprehensive follow-up for efficacy and biomarker validation.
CONDITIONS
Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
P
Peng Ding, Dr
X
Xiaorong Dong, Dr
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Induction period: approximately 12 weeks; Consolidation period: varies until cerebrospinal fluid ctDNA is negative
Participants receive high-dose Firmonertinib daily and intrathecal injections of pemetrexed according to weight-based dosing schedules during induction and consolidation periods to treat EGFR mutant NSCLC with leptomeningeal metastases.
Intrathecal injections on Day 1 and Day 5 of each 3-week cycle for 4 cycles during induction, then injections every 4 weeks during consolidation
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ziyi Xu, Xuezhi Hao, Qi Wang...
https://pubmed.ncbi.nlm.nih.gov/36870951/E Le Rhun, M Weller, M van den Bent...
https://pubmed.ncbi.nlm.nih.gov/37863528/Yuankai Shi, Xingsheng Hu, Shucai Zhang...
https://pubmed.ncbi.nlm.nih.gov/33780662/David M Jackman, Leigh A Cioffredi, Lorraine Jacobs...
https://pubmed.ncbi.nlm.nih.gov/25784657/Weiwei Yan, Yang Liu, Ji Li...
https://pubmed.ncbi.nlm.nih.gov/31521171/Jessica A Wilcox, Ugonma N Chukwueke, Myung-Ju Ahn...
https://pubmed.ncbi.nlm.nih.gov/38902944/Jiyun Lee, Yoon La Choi, Joungho Han...
https://pubmed.ncbi.nlm.nih.gov/32652216/Rongbin Qi, Xinyu Fu, Yingying Yu...
https://pubmed.ncbi.nlm.nih.gov/37604026/James C H Yang, Sang-We Kim, Dong-Wan Kim...
https://pubmed.ncbi.nlm.nih.gov/31809241/C Fan, Z Jiang, C Teng...
https://pubmed.ncbi.nlm.nih.gov/38377785/Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor